Terazosin Chemical Properties

Melting point:

281-283°C

Boiling point:

664.5±65.0 °C(Predicted)

Density 

1.332±0.06 g/cm3(Predicted)

storage temp. 

-20°C Freezer

solubility 

H₂O: 25 mg/mL

form 

powder

pka

pKa (0.1N NaOH): 7.1(at 25℃)

color 

white to off-white

Water Solubility 

30.6mg/L(22.5 ºC)

BCS Class

1/3

InChIKey

VCKUSRYTPJJLNI-UHFFFAOYSA-N

CAS DataBase Reference

63590-64-7(CAS DataBase Reference)

Safety Information

Hazard Codes 

Xn,Xi

Risk Statements 

22-36/37/38

Safety Statements 

26-36

WGK Germany 

3

RTECS 

TK8044925

MSDS

• Language:English Provider:Terazosin
• Language:English Provider:SigmaAldrich

Terazosin Usage And Synthesis

Chemical Properties

White to Off-White Crystalline Powder

Uses

An α-1-adrenergicblocker related to prazosin.

Uses

Terazosin is used for the same indications as is prazosin; however, it has the advantage of being able to be used once a day.

Uses

An a-1-adrenergicblocker related to prazosin

Definition

ChEBI: Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist.

Clinical Use

Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH)

Synthesis

Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)- piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a tetrahydrofuryl radical. It is synthesized in exactly the same manner except using 1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51].

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension when used in combination.

Metabolism

Terazosin is metabolised in the liver; one of the metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the urine, as unchanged drug and metabolites.

Terazosin(63590-64-7)Related Product Information

• Piperacillin
• Dimethyldimethoxysilane
• N-Aminoethylpiperazine
• Tris(hydroxymethyl)aminomethane
• 6-Aminocaproic acid
• Diphenyldimethoxysilane
• CARBONYL SULFIDE
• Glycine
• 3-Aminophenol
• ALTRENOGEST
• 1,1-Dimethoxyethane
• PYRAZOPHOS
• Terazosin hydrochloride
• TERAZOSIN RELATED COMPOUND C (25 MG) (1,4-BIS(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)PIPER-AZINE DIHYDROCHLORIDE)
• TERAZOSIN RELATED COMPOUND B (50 MG) (1-(4-HYDROXY-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-[(TETRA-HYDRO-2-FURANYL)CARBONYL]PIPERAZINE)
• Terazosin hydrochloride dihydrate
• 2-chloro-4-amino-6,7-dimethoxyquinazoline (intermediate of terazosin)
• Quinazoline